Assessment and Management of Transplant Renal Artery Stenosis. A Literature Review.

Ann Vasc Surg

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Vascular Surgery Unit, IRCCS University Hospital, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Published: May 2022

Background: Transplant renal artery stenosis (TRAS) following kidney transplantation is a possible cause of graft failure. This review aimed to summarize the evidence about physiopathology, diagnosis and early and late effectiveness of the endovascular treatment (EVT), including angioplasty and stenting procedures.

Methods: A literature research was performed using Pubmed, Scopus and the Cochrane Library databases (January 2000-September 2020) according to PRISMA guidelines. Studies were included if they describe EVT, percutaneous transluminal angioplasty or stent placement of TRAS, published in English and with a minimum of ten patients.

Results: Fifty-six studies were included. TRAS incidence ranges from 1% up to 12% in transplanted kidneys. The TRAS risk factors were: elderly donor and recipient, cytomegalovirus match status, Class II Donor Specific Antibodies (DSA), expanded donor criteria, delayed graft functioning and other anatomical and technical factors. The highest frequency of TRAS presentation is after 3-6 months after kidney transplantation. The most frequent localization of stenosis was para-anastomotic (ranging from 25% to 78%). In 9 studies, all patients were treated by percutaneous transluminal angioplasty (PTA), in 16 studies all patients received percutaneous transluminal stenting (PTS) and in 21 series patients received either PTA or PTS. The twelve months patency rates after EVT ranged from 72% to 94%. The overall complication rate was 9%, with pseudoaneurysms and hematomas as most frequent complications.

Conclusions: TRAS can be successfully and safely treated through an endovascular approach. Stent delivery seems to guarantee a higher patency rate compared to simple angioplasty, however further studies are needed to confirm these results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.avsg.2022.01.011DOI Listing

Publication Analysis

Top Keywords

percutaneous transluminal
12
transplant renal
8
renal artery
8
artery stenosis
8
kidney transplantation
8
studies included
8
transluminal angioplasty
8
studies patients
8
patients received
8
tras
6

Similar Publications

Restenosis remains a long-standing limitation to effectively maintain functional blood flow after percutaneous transluminal angioplasty (PTA). While the use of drug-coated balloons (DCBs) containing antiproliferative drugs has improved patient outcomes, limited tissue transfer and poor therapeutic targeting capabilities contribute to off-target cytotoxicity, precluding adequate endothelial repair. In this work, a DCB system was designed and tested to achieve defined arterial delivery of an antirestenosis therapeutic candidate, cadherin-2 (N-cadherin) mimetic peptides (NCad), shown to selectively inhibit smooth muscle cell migration and limit intimal thickening in early animal PTA models.

View Article and Find Full Text PDF

Objective: This study aimed to examine the effect of drug-coated balloons (DCBs) on vascular luminal dilatational remodeling (VLDR) following simple balloon angioplasty.

Methods: A retrospective cohort study was conducted using data from patients diagnosed with intracranial atherosclerotic stenosis (ICAS), who were treated exclusively with balloon angioplasty at Henan Provincial People's Hospital between June 2019 and April 2023. Inverse probability weighting (IPW) was used to create balanced cohorts of patients who underwent drug-coated balloon angioplasty (DCBA) and plain old balloon angioplasty (POBA).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the role of inflammation-related biomarkers (SII, SIRI, NLR, PLR) in predicting mid-term mortality and restenosis in patients with peripheral artery disease (PAD).
  • During an average follow-up of about 21 months, researchers found that higher levels of these biomarkers correlated with increased mortality rates, particularly highlighting NLR as a significant independent risk factor.
  • However, no significant links were established between these biomarkers and the occurrence of restenosis in the study participants.
View Article and Find Full Text PDF

Objective: To describe the treatment outcomes of patients who underwent Percutaneous Transluminal Angioplasty (PTA) for Central Vein Occlusive Disease (CVOD) in end-stage kidney disease and determine the association between patient profile and treatment outcomes.

Methods: A single-institution, retrospective review of patients aged 18 and above with end-stage kidney disease who underwent PTA for CVOD in the University of the Philippines - Philippine General Hospital (UP-PGH) from January 1, 2013, to December 31, 2022, was performed. These patients' demographic and clinical profiles were evaluated using means, frequencies, and percentages.

View Article and Find Full Text PDF

Peritherapeutic intra-arterial flow changes predict long-term stent patency in patients with severe intracranial artery stenosis receiving PTAS.

Eur J Radiol

December 2024

Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:

Background And Purpose: The quantitative intra-arterial flow dynamics following percutaneous transluminal angioplasty and stenting (PTAS) for severe intracranial artery stenosis have never been investigated. We aimed to evaluate peritherapeutic intracranial artery flow dynamics following PTAS with quantitative magnetic resonance angiography (qMRA) to predict long-term stent patency.

Design: This is a prospective, single-center study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!